Search

Your search keyword '"Hide, Michihiro"' showing total 1,112 results

Search Constraints

Start Over You searched for: Author "Hide, Michihiro" Remove constraint Author: "Hide, Michihiro"
1,112 results on '"Hide, Michihiro"'

Search Results

2. Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan

3. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

4. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema

5. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

8. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

13. Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan

15. The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)

16. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)

17. Survey of hereditary angioedema episodes and quality of life impairment through a patient-participatory registry

18. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

20. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021

24. Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

25. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

35. The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project

37. Japanese guidelines for atopic dermatitis 2020

45. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

46. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

47. HLA-DQ and RBFOX1 as susceptibility genes for an outbreak of hydrolyzed wheat allergy

48. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Catalog

Books, media, physical & digital resources